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Summary In a group of seventy patients with small cell lung cancer the prognostic value of serum tumour
markers was determined. Thymidine kinase (TK), tissue polypeptide antigen (TPA) and lactate dehydrogenase
(LDH) but not neuron specific enolase (NSE) correlated significantly with survival. Since all markers were
strongly interrelated with each other and with the extent of disease, the combined determination of TK, TPA
and LDH or the combination of disease extent and a marker yielded no more prognostic information than a
single measurement of one of these variables.
Well established prognostic factors in small cell lung cancer
(SCLC) are performance status (PS) and extent of disease
(Maurer et al., 1981). Recently several groups have intro-
duced biochemical data such as liver function tests, LDH,
alkaline phosphatase, albumin haemoglobin, white blood cell
count and bicarbonate to delineate prognostic subgroups in
combination with PS and extent of disease or even as a
replacement of extent (Souhami et al., 1985, Cerny et al.,
1987). The prognostic significance of such biochemical data is
probably either related to the tumourload and/or the site of
metastases. The disadvantage of such an approach is that
these data are an indirect reflection of the tumour. It seems
more logical to investigate tumour derived products, which
may give a direct estimation of the total body tumourload in
a more refined way than the usual distinction between limited
(LD) and extensive disease (ED). Several studies have been
published on the prognostic value of tumour markers, but
only few have compared the relative value of different prog-
nostic factor (Deuss et al., 1987; Buccheri et al., 1987; Carney
et al., 1982).
The purpose of this study was to determine the prognostic
value of three tumour markers for response and survival in
comparison with LDH, PS and extent of disease in a group
of uniformly staged and treated patients.
Materials and methods
Patients
Pretreatment blood samples were obtained from 70 con-
secutive, previously untreated patients with a histological
diagnosis of undifferentiated small cell carcinoma of the lung.
Minimal staging procedures for all patients included physical
examination, chest X-ray, computed tomography scan or
ultrasound of the upper abdomen, bone scan and unilateral
bone-marrow biopsy. Limited disease (LD) was defined as
disease confined to one hemithorax including ipsilateral hilar,
mediastinal lymph nodes, and supraclavicular lymph nodes
and extensive disease (ED) as disease spread beyond the
hemithorax including extension to the chest wall or to the
contralateral lung. In 61 patients, chemotherapy consisted of
doxorubicin 45 mg m-2 intravenously (IV) on day 1, cyc-
lophosphamide 1000 mg m2 IV on day 1, and etoposide
100mg m2 IV on days 1, 3 and 5, repeated every 3 weeks
for at least five cycles provided no progression occurred. The
nine remaining patients were treated with various chemo-
therapy regimens in most instances including a combination
of carboplatin or cisplatin and etoposide or ifosfamide.
Disease response was evaluated according to standard WHO
criteria after every two or five courses. Patients with rapidly
progressive disease after one course of chemotherapy were
documented as progressive disease. Survival was recorded
from the start of treatment to death.
Marker assessment
NSE was measured with the Pharmacia NSE RIA test (Phar-
macia AB, Uppsala, Sweden) as is described previously (Coo-
per et al., 1985). Serum concentrations above 12.5 ng ml-'
were considered to be pathological. Serum TK activity was
determined by the method of Gronowitz (Gronowitz et al.,
1984) using a commercial radioenzymatic assay (Sangtec
Medical Co, Bromma, Sweden) with '25iodo deoxyuridine as
a substrate. TK levels above 5 U ml-' were considered as
abnormal. TPA measurements were performed using a com-
mercial kit (Prolifigen RIA Sangtec Medical Co, Bromma,
Sweden). The cut-off level for normal TPA values was
100 U-'.
Statistical methods
The variables NSE, TK, TPA and LDH were log trans-
formed before calculation of correlation coefficients and Cox
regression analysis. Extent of disease was classified and coded
as 1 = limited disease and 2=extensive disease. Response
was classified and coded as 1 = complete response, 2 = par-
tial response and 3 = no response. The strength of the
association between the markers, extent of disease, perfor-
mance status, response and survival was expressed using
linear correlation coefficients. However, Cox's regression
analysis was applied to determine the relative importance of
the prognostic factors on survival.
Results
Clinical characteristics are shown in Table I. Follow-up at
time of analysis was completed for all patients but one, who
was still alive 140 weeks after start of treatment. Pretreat-
ment levels of serum NSE, TK and TPA could be determined
in 69, 70 and 61 patients respectively. The percentage of
patients with elevated markers in relat on to the extent of
disease is shown in Table II. Median I[SE for patients with
LD was 23ngml' (range 8-132), anId 71 ngml[l (range
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Table I Patient characteristics
No. patients
Median age (years)
Sex
male
female
Median performance status (Karnofsky)
Limited disease
Extensive disease
Response
complete response
partial response
stable disease
progression
non-evaluable
Median survival all patients (weeks)
median survival limited disease
median survival extensive disease
70
63 (range 36-75)
54 (77%0
16 (13%)
70 (range 30-100)
29 (41%)
41 (59%)
27 (39%)
30 (43%)
5 ( 7%)
3 ( 4%)
5 ( 7%)
40 (range 0-143)
56 (range 13-140)
30 (range 0-143)
Table III The correlation coefficients between the markers, LDH,
according to performance score, response and survival
Parameters
NSE TK TPA LDH PS Resp. Surv.
NSE 1
TK 0.57
TPA 0.71 0.61 1
LDH 0.72 0.70 0.84 1
PS -0.42 -0.44 -0.51 -0.57 1
Resp. 0.31 0.58 0.49 0.57 - 0.34 1
Surv. - 0.13 - 0.37 - 0.37 - 0.35 0.25 - 0.62 1
Abbreviations: NSE = log (neuron specific enolase); TK = log
(thymidinekinase); TPA = log (tissuepolypeptide antigen); LDH = log
(lactate dehydrogenase); PS = performance score according to Kar
nofsky; Resp. = response; Surv. = survival; LD = limited disease;
ED = extensive disease.
Table II Percentageofpatientswithelevatedmarkers inrelation tothe
extent of disease
No. ofpatients and (%)
Extent ofdisease NSE TK TPA
Limited disease 26 (90) 11 (38) 9 (36)
Extensive disease 38 (95) 28 (68) 27 (79)
8-626) for patients with ED. Median TK and TPA for
patients with LD were 5 UI-' (range 2-15) and 63 UI-'
(range 17-311) respectively, and 17 U I-' (range 2-400) and
311 U 1-' (range 24-7076) for patients with ED.
The correlation coefficients between the serum markers,
LDH, Performance score according to the Karnofsky index,
response and survival are shown in Table III. A significantly
intermarker correlation was observed and also between the
markers and serum LDH. An example of a scatter diagram
of TPA and NSE is depicted in Figure 1. All markers as well
as LDH correlated with the stage of disease. This correlation
was even more pronounced when patients with extensive
disease were subdivided into two groups: patients with metas-
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tases to only one organ site for example only liver metastases
or only bone metastases (ED-1), and patients with metas-
tases to more than one organ site (ED-2) (Table IV). In
univariate analyses PS, disease extent, TK, TPA and LDH
were all variables significantly correlated with survival. NSE
on the contrary was not significantly correlated with survival
(Table V). Since many of the above mentioned variables were
interrelated, a multivariate analysis of the various factors has
been performed in order to determine their relative prognos-
tic importance. In the final model only TK remained as an
significant prognostic factor. Addition of one of the other
variables or extent of disease to a model with TK did not
improve the fit of the model (P>0.10). However due to the
relative limited sample size and the observed standard error it
could not be significantly shown that TK was a better prog-
nostic factor than TPA, LDH or extent of disease.
Discussion
The evaluation of prognostic factors may serve different pur-
poses such as choice of treatment, individual prognostication,
comparison of different trials or trialarms and gathering
knowledge about the heterogeneity and biological behaviour
of the disease.
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Figure 1 Scatter diagram of NSE and TPA.
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TableIV Correlationcoefficientsand95% confidenceintervalsbetweenTK,TPA,NSE,
LDH and disease extent
TK TPA NSE LDH
Extent 0.59 (0.41-0.72) 0.54 (0.33-0.70) 0.44 (0.23-0.61) 0.48 (0.26-0.65)
Abbreviations: TK = log (thymnidine kinase); TPA = log (tissue polypeptide antigen;
NSE = log(neuron specificenolase); LDH = log (lactatedehydrogenase); Extent = stage
ofdiseasegrouped aslimiteddisease, extensivedisease-I andextensivedisease-2(seetext).
Table V Results ofunivariate Cox's proportional hazards regression
analyses
Variable Regression coefficient SE P
TK 0.44 0.13 0.001
NSE 0.13 0.14 0.36
TPA 0.37 0.12 0.003
LDH 0.56 0.20 0.008
Extent 0.65 0.25 0.01
Abbreviations: TK = log (thymidine kinase); TPA = log (tissue
polypeptide antigen); NSE = log (neuron specific enolase); LDH = log
(lactate dehydrogenase); Extent grouped as limited disease and
extensive disease.
The prognosis is depen'dent on the combined effects of
prognostic factors and therapy, which therefore understand-
ably are frequently linked. In case of chemotherapy the
prognosis will be mainly determined by the total body
tumourload, the fraction of chemotherapy-resistant cells,
either predetermined or acquired, and the growth rate of the
latter. Theoretically one or a combination of marker sub-
stances, which will reflect one of the above mentioned
prognostic factors, would seem to be ideal. One of the pre-
requisites for such a marker would be that the amount,
which is released or secreted per gram of tumour tissue, is
independent of tumour heterogeneity or correlated with a
prognostically important difference in biological behaviour.
In this study it was found that NSE, TK, TPA and LDH
were significantly correlated with the extent of disease, with
each other and with PS. TK, TPA and LDH but not NSE
were also significantly correlated with survival. The former
observations are in agreement with previous reports (Deuss
et al., 1987; Buccheri et al., 1987; Gronowitz et al., 1986).
The latter observation is not supported by the studies of
Akoun et al. (1985) and Jorgensen et al. (1988) who showed
that NSE is a significant prognostic factor for survival. The
combined lack of correlation between NSE and both res-
ponse and survival suggests that treatment related factors
may be involved, i.e. that in contrast to the studies of Akoun
et al. (1985) and Jorgenson et al. (1988) in our study a
population of tumour cells is killed, which is correlated less
with the serum NSE level. Approximately 85% of the pa-
tients in our study received a three-drug regimen consisting
of cyclophosphamide, doxorubicin and etoposide. In the
Danish study (Jorgenson et al., 1988) the patients received
three different regimens, each of which contained at least six
different drugs such as CCNU, cyclophosphamide, vincris-
tine, etoposide, doxorubicin, cisplatin, vindesine and hex-
amethylmelamine. In the French study (Akoun et al., 1985)
patients received four different drugs (cyclophosphamide,
doxorubicin, vincristine and methotrexate). Although very
different to prove it may be well that especially in the Danish
study the six drugs killed a somewhat different population of
tumour cells than the three drugs in our study. This may
explain why serum NSE as a reflection of the tumourload is
correlated with prognosis in one study and not the other.
TK, TPA, LDH and extent of disease all had significant
prognostic capacity in the univariate analysis, however in the
multivariate analysis it was shown that the combination of
c
0
0 0.
0
0. a,
E
0
Weeks
Figure 2 Kaplan-Meier survival curve for different groups of
patients based on their TK level. 1 = TK < 6 U ml; 2 = 6
Uml<TK <18Uml; 3=TK>18Uml.
extent of disease and TK, TPA or LDH yielded no more
prognostic information than the measurement of one of these
parameters. Even a combination of the various markers
didn't improve upon the significance of a single marker. This
latter observation may suggest that all these markers are
picking out the same cells or bear the same relationship with
the total tumourload.
Besides the fact that TK seems to be a good indicator of
the total tumour mass it could have been assumed that there
might be a relation between TK and the proliferative activity
of the tumours of patients with small cell lung cancer since
TK is involved in the process of DNA synthesis. Clinical
evidence for the relation of TK and growth rate has been
provided by the study of Greengard el al. (1985) in which it
has been observed that TK concentrations of biopsy samples
bear a quantitative inverse correlation to the volume doub-
ling time of lung neoplasms as determined by tumour
diameter measurements from sequential chest X-rays. How-
ever, if TK in SCLC relates with tumour growth rate this
would most probably result in different responses to treat-
ment for tumours based on their TK levels resulting in
survival curves with different slopes (Shackney et al., 1978).
Survival curves calculated by the Kaplan-Meier method for
different groups of patients based on their TK levels are
depicted in Figure 2. Since the slopes of both depicted sur-
vival curves are identical this suggests that the prognostic
capacity of TK is most probably entirely tumourload related.
In conclusion, in this study TK, TPA, LDH and extent of
disease, but not NSE, proved to be valuable prognostic
factors for prediction of survival. The prognostic significance
of all these variables seems to be entirely tumourload related.
Further studies including more patients are warranted to
evaluate whether a single measurement of a marker can
replace a crude distinction between LD and ED determined
through a complicated staging procedure.372 A. VAN DER GAAST et al.
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